Sarcomatoid carcinomas (SC) are a rare histologic variant of prostate cancer associated with progression in the absence of PSA elevation (1) and overall, a poor prognosis (2).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
These tumours commonly present alongside conventional adenocarcinoma and can show immunohistochemical (IHC) evidence of prostatic origin (3). However, loss of expression of the androgen receptor (AR) and AR-regulated proteins (including PSA and ERG in ERG gene-fusion positive cancers) in SC could introduce a diagnostic dilemma as to whether a second primary has occurred. Moreover, IHC is unable to conclusively establish whether SC and has the same origin as co-occurring adenocarcinomas have a common origin.
Rodrigues DN, Hazell S, Miranda S, Crespo M, Fisher C, de Bono JS, Attard G. Are you the author?
Section of Medicine, The Institute of Cancer Research, London.
Reference: Histopathology. 2014 Jul 12. Epub ahead of print.